As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of bulevirtide for treating chronic hepatitis D.
Following on from the email that was sent during March 2021 where we informed consultees and commentators that this appraisal was paused due to the company requesting a delay with timelines of this appraisal whilst further clinical evidence was collected. I am now writing to inform that we will be restarting the appraisal in November (invitation to participate will be reissued) with an anticipated deadline for submissions expected in approximately mid- January 2022 and an appraisal committee meeting date anticipated for mid-July 2022.